Replies to post #136937 on Biotech Values

[steveporsche]

Quote:
--------------------------------------------------------------------------------
CLDX -So, I don't understand why someone would key in on 110 when trying to come up with a fair valuation for CLDX and ignore 011. Doesn't make much sense to me.
--------------------------------------------------------------------------------

That is why I wrote "FWIW". Personally, I think most of the biotech analysts take the current stock price and add 20% if they like the stock or subtract 20% if they dislike it, and totally make up the rest of their assumptions to fit their target price.

[bladerunner1717]

CLDX prices offering


Celldex Prices Public Offering of Common Stock
Business WirePress Release: Celldex Therapeutics, Inc. – 1 hour 23 minutes ago



Celldex Therapeutics, Inc.

RELATED QUOTES
Symbol Price Change
CLDX 3.96 -0.40

NEEDHAM, Mass.--(BUSINESS WIRE)--

Celldex Therapeutics, Inc. (Nasdaq: CLDX - News) today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock. The net proceeds to Celldex from this offering are expected to be approximately $37,744,500, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Celldex. Celldex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. All of the shares in the offering are to be sold by Celldex. The offering is expected to close on or about February 29, 2012, subject to customary closing conditions.

Jefferies & Company, Inc. is acting as the sole book-running manager of the offering. Wedbush PacGrow Life Sciences, Oppenheimer & Co., Brean Murray, Carret & Co. and Roth Capital Partners, LLC are acting as co-managers of the offering.

Celldex anticipates using the net proceeds from the offering to fund Celldex’s clinical trials of its product candidates and for working capital and other general corporate purposes.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and is effective. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement relating to these securities, when available, may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at [e-mail].

Bladerunner